HomeCompareNINOF vs ABBV

NINOF vs ABBV: Dividend Comparison 2026

NINOF yields 1.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.4K in total portfolio value
10 years
NINOF
NINOF
● Live price
1.97%
Share price
$13.68
Annual div
$0.27
5Y div CAGR
-17.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$30.23
Full NINOF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NINOF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNINOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NINOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NINOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NINOF
Annual income on $10K today (after 15% tax)
$167.76/yr
After 10yr DRIP, annual income (after tax)
$25.70/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,030.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NINOF + ABBV for your $10,000?

NINOF: 50%ABBV: 50%
100% ABBV50/50100% NINOF
Portfolio after 10yr
$61.6K
Annual income
$12,400.99/yr
Blended yield
20.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NINOF
No analyst data
Altman Z
1.9
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NINOF buys
0
ABBV buys
0
No recent congressional trades found for NINOF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNINOFABBV
Forward yield1.97%3.06%
Annual dividend / share$0.27$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-17.6%40.6%
Portfolio after 10y$20.9K$102.3K
Annual income after 10y$30.23$24,771.77
Total dividends collected$814.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NINOF vs ABBV ($10,000, DRIP)

YearNINOF PortfolioNINOF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,863$162.63$11,550$430.00$687.00ABBV
2$11,759$136.05$13,472$627.96$1.7KABBV
3$12,696$113.41$15,906$926.08$3.2KABBV
4$13,679$94.30$19,071$1,382.55$5.4KABBV
5$14,714$78.24$23,302$2,095.81$8.6KABBV
6$15,809$64.81$29,150$3,237.93$13.3KABBV
7$16,969$53.63$37,536$5,121.41$20.6KABBV
8$18,202$44.33$50,079$8,338.38$31.9KABBV
9$19,512$36.62$69,753$14,065.80$50.2KABBV
10$20,908$30.23$102,337$24,771.77$81.4KABBV

NINOF vs ABBV: Complete Analysis 2026

NINOFStock

Nikon Corporation manufactures and sells optical instruments in Japan, North America, Europe, China, Thailand, and internationally. It operates through Imaging Products Business, Precision Equipment Business, Healthcare Business, Components Business, and Industrial Metrology and Others segments. The Imaging Products Business segment provides digital SLR cameras, compact digital cameras, and interchangeable camera lenses. The Precision Equipment Business segment offers FPD lithography systems and semiconductor lithography systems. The Healthcare Business segment provides biological microscopes, cell culture observation systems, and ultra-wide field retinal imaging devices, as well as products and services related to the contract cell development and manufacturing field. The Components Business segment offers optical components, optical parts, encoders, and material processing products and services; EUV-related components and space-related solutions; and photomask substrates for FPDs. The Industrial Metrology and Others segment provides industrial microscopes, non-contact 3D metrology systems, measuring instruments, X-ray/CT inspection systems, and surveying instruments. The company also offers optical lenses, sport optics products, optical glasses, molded optical glasses, camera components, and ophthalmic lenses. In addition, it sells used equipment; provides maintenance services for FPD/semiconductor lithography systems; sells and services cameras, microscopes, measuring instruments, and X-ray inspection equipment; and develops and supports computer software. Further, the company is involved in the procurement, logistics, and employee welfare activities; development, manufacturing, and testing services for cell-based therapeutics; and assembly of camera units. Nikon Corporation was incorporated in 1917 and is headquartered in Tokyo, Japan.

Full NINOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NINOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NINOF vs SCHDNINOF vs JEPININOF vs ONINOF vs KONINOF vs MAINNINOF vs JNJNINOF vs MRKNINOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.